17.37
0.45 (2.66%)
Previous Close | 16.92 |
Open | 16.86 |
Volume | 118,458 |
Avg. Volume (3M) | 162,222 |
Market Cap | 1,068,545,152 |
Price / Sales | 60.23 |
Price / Book | 8.60 |
52 Weeks Range | |
Earnings Date | 27 Mar 2025 |
Diluted EPS (TTM) | -0.990 |
Total Debt/Equity (MRQ) | 7.24% |
Current Ratio (MRQ) | 15.58 |
Operating Cash Flow (TTM) | -40.08 M |
Levered Free Cash Flow (TTM) | -19.59 M |
Return on Assets (TTM) | -43.61% |
Return on Equity (TTM) | -77.86% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
Medical Instruments & Supplies (Global) | Bearish | Bearish | |
Stock | Pulse Biosciences, Inc | Mixed | Mixed |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | 2.0 |
Technical Moving Averages | -1.0 |
Technical Oscillators | -0.5 |
Average | -0.38 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Small Growth |
% Held by Insiders | 74.00% |
% Held by Institutions | 8.64% |
Ownership
Name | Date | Shares Held |
---|---|---|
Panoramic Capital, Llc | 31 Dec 2024 | 48,571 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
08 May 2025 | Announcement | Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results |
06 May 2025 | Announcement | Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference |
01 May 2025 | Announcement | Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting |
25 Apr 2025 | Announcement | Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
24 Apr 2025 | Announcement | Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 |
23 Apr 2025 | Announcement | Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |